Genmab

International biotech company dedicated to improving the lives of people with cancer & other serious diseases through antibodies.

[Genmab @Genmab]

#InvestorUpdate: Genmab reported financial results for the first nine months of 2026.

Watch our Q3 webcast for updates on our pipeline, strategic priorities and continued progress as an integrated biotech: https://t.co/mhH0ag34Ux.

[Genmab @Genmab]

#NewsUpdate: We’re looking forward to #ASH26, where new and exciting clinical data will be shared. Our research will feature multiple abstracts highlighting our latest advances across various types of #BloodCancer.

Learn more: https://t.co/lwKsAYiwFA

[Genmab @Genmab]

#InvestorUpdate | Mark your calendar for November 5: Genmab will release our interim report for the first nine months of 2026.

Join us to learn about our strategic priorities, growth as an integrated biotech and progress in advancing innovative antibody medicines for patients.

Register here: https://t.co/8EcwAHhRuQ.

[Genmab @Genmab]

Today, we announced positive Phase 3 topline results for our investigational therapy in head and neck cancer. The findings reinforce the potential of our differentiated antibody science and reflect our continued commitment to developing transformative medicines for people living with cancer.

Learn more: https://t.co/9rHD68RA2X.

[Genmab @Genmab]

#InvestorUpdate: Tune in to Genmab’s upcoming investor event on October 28th at 12:00pm EST for a high-level overview of recent data.

View event details and access the webcast: https://t.co/7vavA49QYJ.

[Genmab @Genmab]

We shared new research in recurrent or metastatic head and neck squamous cell carcinoma (#HNSCC), a disease where significant needs remain, at @myESMO.(1) We are grateful to the investigators, study participants, and healthcare professionals who help to advance #AntibodyScience research for this patient community.

Learn more: https://t.co/9rHD68RA2X. #ESMO26

1. Ionna, et al. (2021). Recurrent/metastatic squamous cell carcinoma of the head and neck. Cancers, 13(10), Article 2371. https://t.co/3TfXlyDrtw

[Genmab @Genmab]

At @myESMO, we presented new research in metastatic colorectal cancer, where there remains a need for continued progress.(1) We are proud to stand alongside the oncology community in advancing the development of potential therapeutic options for people affected by cancer.

Learn more: https://t.co/9rHD68RA2X. #ESMO26

1. Ionna, et al. (2021). Recurrent/metastatic squamous cell carcinoma of the head and neck. Cancers, 13(10), Article 2371. https://t.co/3TfXlyDrtw

[Genmab @Genmab]

We’ve announced a clinical trial collaboration with @Incyte to evaluate a novel combination of investigational therapies with standard-of-care chemotherapy, reflecting our shared commitment to cancer research.

Learn more: https://t.co/uesBbLBXeP.

[Genmab @Genmab]

Today, we announced the first Phase 3 results for one of our investigational therapies in ovarian cancer. These data mark a milestone for our gynecologic cancer portfolio and build on our hope in its potential for patients living with ovarian cancer.

Learn more: https://t.co/9rHD68RA2X.

[Genmab @Genmab]

Genmab is supporting @BloodCancerUtd's Light the Night Walk in Mercer County, NJ, once again. This is an amazing opportunity to come together to celebrate survivors, support those living with blood cancer and remember loved ones lost.

Register for an event in your community here: https://t.co/1IfZ75R3tm.

#LightTheNight #InspiredbyPatients

[Genmab @Genmab]

Welcome to a new edition of #AntibodyHour 🕙!

Watch to hear our colleague Marcia Kruidhof, Clinical Trial Manager, share what motivates her, how collaboration helps teams find solutions, and what Genmab’s patient-focused approach to research means to her.

#PatientFirst

[Genmab @Genmab]

En 2023, le cancer du col de l’utérus figure parmi les cancers les plus fréquents chez les femmes âgées de 15 à 44 ans en France.(3) Nous œuvrons à faire progresser l’innovation avec un objectif : contribuer à améliorer les résultats pour les patientes. #CervicalCancer #WomensHealth

[Genmab @Genmab]

We’re excited to attend this year’s @myESMO Congress and connect with experts in the field.

To learn more about our pipeline of innovative antibodies, visit booth #8022 in Exhibit Hall 8 and click here: https://t.co/mUdJ035FUH.

#Oncology #ESMO2026

[Genmab @Genmab]

During this edition of #AntibodyHour 🕙, we spotlight our colleague Iris Kolder, Director, Translational and Clinical Data Science.

Iris shares what motivates her work to bring medicines to patients, how she sees the people behind the data, and how her experience as a cancer survivor brings personal meaning to what she does each day.

#AntibodyScience

[Genmab @Genmab]

#NewsUpdate: Topline results from a phase 3 study in newly diagnosed diffuse large B-cell #lymphoma (#DLBCL) are now available for our therapy in partnership with @abbvie.

Learn more: https://t.co/KHYFxhHwSr

[Genmab @Genmab]

At #IGCS2026, we shared new Phase 1/2 data evaluating one of our investigational therapies in #OvarianCancer.

These results add to the growing body of evidence supporting our clinical program in #GynecologicCancers.

Hear from Dr. Elizabeth Lee.

Learn more: https://t.co/9twKySXWCm.

[Genmab @Genmab]

This #WorldLymphomaDay, we’re sharing how we’re working to change the course of care for patients and the larger #lymphoma community.

[Genmab @Genmab]

Today, Genmab colleagues participated in Global Volunteer Day: volunteering 3000+ hours for 50+ local charities in the communities where we live and work.

Learn more here: https://t.co/qwEWF7u6p7.

#CommunityAtGenmab

[Genmab @Genmab]

We’re heading to #SOHO2026!

Connect with Genmab colleagues at the 14th Annual @SocietyofHemOnc Meeting and visit Booth #176 to learn more about our innovative antibody science and investigational therapies.

#Hematology